AUTH/2415/6/11 - Director v Biogen Idec

Tysabri DVD

  • Received
    27 June 2011
  • Case number
    AUTH/2415/6/11
  • Applicable Code year
    2011
  • Completed
    04 August 2011
  • Breach Clause(s)
    9.1 and 22.1
  • Sanctions applied
    Undertaking received
  • Additional sanctions
  • Appeal
    No appeal
  • Review
    November 2011

Case Summary

Leo Pharma advised the Authority that a Tysabri (natalizumab) DVD produced and distributed by Biogen Idec to health professionals and patients included a film clip demonstrating Leo's product Xamiol Gel (calcipotriol/betamethasone) on psoriasis (Case AUTH/2413/6/11). It thus appeared that Xamiol Gel, a prescription only medicine, might have been advertised to the public. In accordance with the Authority's Constitution and Procedure this matter was taken up with Biogen Idec as as a complaint under the Code.

The detailed response from Biogen Idec is given below.

The Panel noted that due to human error on a production run at a third party DVD manufacturer, promotional material for Xamiol had been placed on a DVD provided to patients who had been prescribed Tysabri.

A prescription only medicine had thus been promoted to the public, and the Panel ruled that Biogen Idec was in breach of the Code.

The Panel noted that Biogen Idec had certified the DVD in question in August 2010. Biogen Idec had engaged a different company to manufacture the DVD in 2011. The Panel noted that the manufacturing process involved uploading the approved electronic file on to the DVD; a process which was open to human error. The Panel noted the risk of human error and the serious consequences if such risk materialized in relation to material directed at patients. The Panel considered it would have been good practice for Biogen Idec, prior to distribution, to have checked a DVD from the production run against that certified by the company.

The Panel considered that the quality checks that Biogen Idec put in place as a result of this complaint should have been in place from the outset. These checks were particularly important when the material produced was intended for patients. High standards had not been maintained, and a breach of the Code was ruled.

The Panel did not consider that the circumstances brought discredit upon or reduced confidence in the pharmaceutical industry and no breach of Clause 2 was ruled.